Observational Study in Preterm Neonates Who Are Sufficiently Stable on Non-Invasive Ventilatory Support
An Oligo-center Observational Study to Collect Data in Preterm Neonates Born at or Above 27+0 Weeks of Gestational Age Who Are Sufficiently Stable on Non-Invasive Ventilatory Support
2 other identifiers
observational
40
1 country
3
Brief Summary
The purpose of this observational study is to collect data on vital signs, oxygen requirements and other data related to ventilator care in preterm neonates under standard of care treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2013
Shorter than P25 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 26, 2013
CompletedFirst Posted
Study publicly available on registry
May 24, 2013
CompletedStudy Start
First participant enrolled
June 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2014
CompletedAugust 22, 2014
August 1, 2014
9 months
April 26, 2013
August 20, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time and failure-adjusted Area Under the Curve (AUC) from Time 0 (T0) to 98 hours after T0 (T47) (AUCT0-T47adjusted) of fraction of inspired oxygen (FiO2)
Fraction of inspired oxygen (FiO2) is the amount of oxygen in the ventilator outlet gas flow.
Beginning of the Intensive observation phase (T0; approximately 45 minutes after birth) to 98 hours after T0
Secondary Outcomes (13)
Time with optimal saturation of peripheral oxygen (SpO2) of 88% to 96%
T0 and at 0.25, 0.5, 0.75 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75 4, 4.25. 4.5, 4.74, 5, 5.25, 5.75, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, and 54 hours
Continuous positive airway pressure (CPAP)-failure necessitating intubation and mechanical ventillation and/or surfactant instillation during observation period from T0 to 98 hours
T0 to 98 hours
Percentage of participants requiring instillation of an approved surfactant preparation
Gestational week (GW) 36+6 days
Percentage of participants with bronchopulmonary dysplasia (BPD) at GW 36
Gestational Week 36
Respiratory rate over time
T0 to Gestational Week 36
- +8 more secondary outcomes
Study Arms (1)
Preterm Neonates
Preterm neonates born at or above 27+0 weeks of gestational age sufficiently stable on nasal continuous positive airway pressure (CPAP) will be treated by standard of care.
Interventions
Eligibility Criteria
Preterm neonates on non-invasive ventilatory support in a hospital setting.
You may qualify if:
- \. Written, informed consent of both parents or legal guardian(s) obtained (on admission, prior to or after delivery).
- \. Preterm neonates born at or above 27+0 gestational weeks (GW) who are sufficiently stable on nasal continuous positive airway pressure (CPAP). Upper limit 36+0 GW.
- \. Participants' minimum weight at birth must be 800 g. Upper weight limit is 2500 g.
- \. CPAP-positive end-expiratory pressure (PEEP) must be ≥5 cm and ≤ 8 cm H2O. 5. Fraction of oxygen (O2) in ventilator outlet gas flow (FiO2) ≥ 30% to reach saturation goal (SpO2 between 88% and 96%) during the time period from B0 to T0.
You may not qualify if:
- \. FiO2 \> 50% to reach saturation goal (saturation of peripheral oxygen (SpO2) between 88% and 96%) during the time period from 30 minutes after birth (B0) to 45 minutes after birth (T0).
- \. Presence of severe respiratory distress syndrome (RDS) necessitating immediate intubation and surfactant rescue at entry into the study, or having necessitated surfactant rescue prior to entry into the study.
- \. Known life-threatening congenital anomaly or genetic syndrome. 4. Participation in an interventional study in parallel to this observational study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Takedalead
Study Sites (3)
Unknown Facility
Hanover, Germany
Unknown Facility
Lübeck, Germany
Unknown Facility
Nuremberg, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Director
Takeda
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 26, 2013
First Posted
May 24, 2013
Study Start
June 1, 2013
Primary Completion
March 1, 2014
Study Completion
March 1, 2014
Last Updated
August 22, 2014
Record last verified: 2014-08